Archive

Research Area: Cardiovascular Health

Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial.

Dikariyanto, V., L. Smith, L. Francis, M. Robertson, E. Kusaslan, M. O’Callaghan-Latham, C. Palanche, M. D’Annibale, D. Christodoulou, N. Basty, B. Whitcher, H. Shuaib, G. Charles-Edwards, P.J. Chowienczyk, P.R. Ellis, S.E.E. Berry, W.L. Hall, 2020. Snacking on whole almonds for 6 weeks improves endothelial function and lowers LDL cholesterol but does not affect liver fat and other cardiometabolic risk factors in healthy adults: the ATTIS study, a randomized controlled trial. Am J Clin Nutr. 00:1– 12.

Background: There is convincing evidence that daily whole almond consumption lowers blood LDL cholesterol concentrations, but effects on other cardiometabolic risk factors such as endothelial function and liver fat are still to be determined. Objectives: We aimed to investigate whether isoenergetic substitution of whole almonds for control snacks with the macronutrient profile of average snack intakes, had any impact on markers of cardiometabolic health in adults aged 30–70 y at above-average risk of cardiovascular disease (CVD). Methods: The study was a 6-wk randomized controlled, parallel-arm trial. Following a 2-wk run-in period consuming control snacks (mini-muffins), participants consumed either whole roasted almonds (n = 51) or control snacks (n = 56), providing 20% of daily estimated energy requirements. Endothelial function (flow-mediated dilation), liver fat (MRI/magnetic resonance spectroscopy), and secondary outcomes as markers of cardiometabolic disease risk were assessed at baseline and end point. Results: Almonds, compared with control, increased endothelium-dependent vasodilation (mean difference 4.1%-units of measurement; 95% CI: 2.2, 5.9), but there were no differences in liver fat between groups. Plasma LDL cholesterol concentrations decreased in the almond group relative to control (mean difference −0.25 mmol/L; 95% CI: −0.45, −0.04), but there were no group differences in triglycerides, HDL cholesterol, glucose, insulin, insulin resistance, leptin, adiponectin, resistin, liver function enzymes, fetuin-A, body composition, pancreatic fat, intramyocellular lipids, fecal SCFAs, blood pressure, or 24-h heart rate variability. However, the long-phase heart rate variability parameter, very-low-frequency power, was increased during nighttime following the almond treatment compared with control (mean difference 337 ms2; 95% CI: 12, 661), indicating greater parasympathetic regulation. Conclusions: Whole almonds consumed as snacks markedly improve endothelial function, in addition to lowering LDL cholesterol, in adults with above-average risk of CVD. This trial was registered at clinicaltrials.gov as NCT02907684.

Whole almond consumption is associated with better diet quality and cardiovascular disease risk factors in the UK adult population: National Diet and Nutrition Survey (NDNS) 2008–2017.

Dikariyanto, V., S.E. Berry, L. Francis, L. Smith, W.L. Hall, 2020. Whole almond consumption is associated with better diet quality and cardiovascular disease risk factors in the UK adult population: National Diet and Nutrition Survey (NDNS) 2008–2017. Eur J Nutr. 60(2):643-654.

Purpose: This work aimed to estimate whole almond consumption in a nationally representative UK survey population and examine associations with diet quality and cardiovascular disease (CVD) risk. Methods: Four-day food record data from the National Diet and Nutrition Survey (NDNS) 2008–2017 (n = 6802, age≥19 year) were analyzed to investigate associations between whole almond consumption and diet quality, measured by the modified Mediterranean Diet Score (MDS) and modified Healthy Diet Score (HDS), and CVD risk markers, using survey-adjusted multivariable linear regression. Results: Whole almond consumption was reported in 7.6% of the population. Median intake in whole almond consumers was 5.0 g/day (IQR 9.3). Consumers had higher diet quality scores relative to non-consumers; higher intakes of protein, total fat, monounsaturated, n-3 and n-6 polyunsaturated fats, fiber, folate, vitamin C, vitamin E, potassium, magnesium, phosphorus, and iron; and lower intakes of trans-fatty acids, total carbohydrate, sugar, and sodium. BMI and WC were lower in whole almond consumers compared to non-consumers: 25.5 kg/m2 (95% CI 24.9, 26.2) vs 26.3 kg/m2 (25.9, 26.7), and 88.0 cm (86.2, 89.8) vs 90.1 cm (89.1, 91.2), respectively. However, there were no dose-related fully adjusted significant associations between increasing almond intake (g per 1000 kcal energy intake) and lower CVD risk markers. Conclusions: Almond intake is low in the UK population, but consumption was associated with better dietary quality and lower CVD risk factors. Habitual consumption of whole almonds should be encouraged as part of a healthy diet.

Anti-atherosclerotic and cardiovascular protective benefits of Brazilian nuts.

C.K.B. Ferrari, 2020. Anti-atherosclerotic and cardiovascular protective benefits of Brazilian nuts. Front Biosci (Schol Ed). 12:38-56.

Brazil nuts are rich in magnesium, selenium, arginine and other amino acids, dietary fiber, tocopherols (vitamin E), phytosterols, linoleic acid, linolenic acid, sitosterols, monounsaturated and polyunsaturated fatty acids, polyphenols and other amino acids. Due to such a rich mixture of nutrients, Brazil nuts protect LDL from peroxidation, and improve endothelial function, blood pressure, lipid metabolism, and decrease endothelial inflammatory markers, DNA oxidation, and blood lipids (cholesterol, LDL, triglycerides). Here, we review and propose biological mechanisms by which bioactive compounds of Brazil nuts afford protections against atherosclerosis and cardiovascular diseases. Just a few nuts per day provide sufficient cardiovascular benefits, including protection against development and progression of atherosclerosis.

The effects of cashew nut intake on lipid profile and blood pressure: A systematic review and meta-analysis of randomized controlled trials.

Jalali, M., M. Karamizadeh, G.A. Ferns, M. Zare, S.P. Moosavian, M. Akbarzadeh, 2020. The effects of cashew nut intake on lipid profile and blood pressure: A systematic review and meta-analysis of randomized controlled trials. Complement Ther Med. 50:102387. doi:10.1016/j.ctim.2020.102387. 

Background: Dyslipidemia and hypertension are important risk factors for cardiovascular disease (CVD). Some studies have suggested that the consumption of nuts may reduce CVD risk. Objective: The present systematic review and meta-analysis was conducted to investigate the efficacy of cashew nut consumption on lipid profile and blood pressure. Methods: PubMed, Embase, Scopus, Web of Science and Cochrane Library were systematically searched to identify randomized control trials (RCTs) examining the effects of cashew nut intake on serum triglycerides (TG), high density lipoprotein-cholesterol (HDL-C), low density lipoprotein-cholesterol (LDL-C), serum total cholesterol (TC), systolic blood pressure (SBP) or diastolic blood pressure (DBP) until 15 November 2019. A random-effects model was used to pool weighted mean difference (WMD) and 95 % confidence intervals (CI). Potential publication bias was assessed using Egger’s test. Sensitivity analysis was performed to assess the impact of each individual study on the pooled results. Results: A meta-analysis on 392 participants showed that cashew nut consumption had no significant effects on lipid profile and DBP. However, there was a significant reduction in SBP (WMD = -3.39, 95 % CI = [-6.13, -0.65], P = 0.01, I2 = 0.0 %) in the group receiving cashew nut compared to the controls. There was no significant publication bias in the meta-analysis. A sensitivity analysis showed that omitting each study did not change the significance of results. Conclusion: This meta-analysis demonstrated that cashew nut consumption might reduce SBP but has no effects on lipid profile and DBP.